Novartis AG stock (CH0012005267): oncology strength and new launches keep investors watching

Novartis AG, one of the world’s largest pharmaceutical groups, recently reported its first-quarter 2026 results and updated investors on progress with key oncology and immunology drugs, underscoring how its reshaped portfolio is supporting earnings and cash flow, according to a company release dated 04/23/2026 and subsequent earnings materials from Novartis.

In the first quarter of 2026, Novartis reported group net sales of around $12.9 billion for the period, with core operating income growing at a mid?single?digit rate year?on?year, supported by drugs such as Kisqali in breast cancer and Entresto in heart failure, according to Novartis financial highlights published on 04/23/2026 and related investor commentary from the company.

On the US market, the American depositary shares of Novartis, which trade under the ticker NVS on the NYSE, closed at about $150 per share on 05/19/2026, reflecting a modest gain on the day, according to closing price data from the New York Stock Exchange as cited by MarketBeat on 05/19/2026.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

Novartis AG: core business model

Novartis focuses on researching, developing and commercializing branded prescription medicines across several therapeutic areas, with a particular emphasis on oncology, cardiovascular, immunology and neuroscience, based on company profile information updated in its recent annual report and corporate overview documents from 2025. The group has increasingly prioritized higher?margin innovative drugs over older, off?patent medicines after strategic portfolio reshaping in recent years.

The company organizes its pharmaceutical activities into major business units centered on innovative medicines and oncology, enabling management to allocate capital and research resources toward assets with the strongest clinical data and commercial potential, according to strategic updates shared at prior Novartis capital markets events and investor presentations in 2025. This structure is designed to streamline decision?making, accelerate launches and focus on specialty treatments that can support pricing power in key markets.

Novartis generates a substantial share of its revenue from the United States, which remains the largest prescription drug market globally, while Europe and other international regions also contribute meaningfully to sales, according to geographic revenue breakdowns disclosed in the company’s 2025 annual report and related filings. For US investors, the prominence of dollar?denominated cash flows and exposure to the American healthcare system makes the stock a way to participate in global pharmaceutical demand while still being anchored in the US market.

Beyond traditional small?molecule medicines, Novartis also invests in biologics and advanced therapies, including targeted treatments and cell?based approaches, though it has sharpened its focus to programs with clearer pathways to approval and commercial viability, according to research and development commentary included in Novartis pipeline updates and R&D briefings held in 2025. The company aims to balance late?stage products that can drive near?term earnings with earlier?stage candidates that could underpin growth into the next decade.

Novartis funds its research and pipeline investments largely through cash flows from existing blockbuster drugs, complemented by selective licensing and collaboration agreements with smaller biotech firms, according to partnership announcements and development deal disclosures in 2024 and 2025. This approach allows the company to access external innovation while maintaining a disciplined stance on deal valuations and integration risk.

Main revenue and product drivers for Novartis AG

Among Novartis’s key growth drivers, Kisqali for advanced breast cancer has emerged as a major contributor, with strong uptake in both the US and international markets during 2025 and into early 2026, as highlighted in therapy?specific sales commentary in the company’s quarterly earnings call materials dated 04/23/2026 and earlier. The drug has benefited from clinical data showing survival benefits, which underpin its position in treatment guidelines and reimbursement decisions.

Cardiovascular medicine Entresto, used in heart failure, remains another pillar of Novartis revenue, registering steady volume growth across regions even as price dynamics vary by market, according to product?level trends discussed in 2025 and first?quarter 2026 financial releases from the company. The medicine’s broadening use in different heart failure patient groups continues to support its sales trajectory, although competition from other therapies is an important factor that investors monitor closely.

In immunology and neuroscience, Novartis has highlighted assets such as Cosentyx, which targets inflammatory conditions, and medicines addressing multiple sclerosis and related indications, based on therapeutic area updates provided during earnings calls and investor presentations in late 2025 and early 2026. These areas contribute to diversifying the revenue base beyond oncology and cardiology, even as pricing and reimbursement negotiations in some markets can weigh on growth rates.

From a pipeline perspective, Novartis is moving forward with several late?stage trials in oncology and immune?mediated diseases intended to support label expansions or new indications for existing drugs, as detailed in clinical development pipelines included in company R&D updates published in 2025 and referenced again in early?2026 investor communication. Successful data readouts and regulatory submissions from these programs could extend the commercial life of current products or unlock new revenue streams.

The company also continues to invest in earlier?stage programs that leverage targeted mechanisms of action and biomarker?driven patient selection, a strategy that reflects broader industry trends toward precision medicine, according to Novartis research strategy explanations in its 2025 annual report and associated scientific briefings. For shareholders, the mix of near?term launch candidates and longer?term scientific bets can influence both earnings visibility and perceived risk.

Beyond individual products, Novartis’s revenue profile is affected by currency movements, with the strong US dollar in recent years impacting reported results when foreign sales are translated back into the reporting currency, according to management commentary in 2025 and early?2026 earnings discussions. The company has emphasized underlying constant?currency growth rates in its communication, which it argues more accurately reflect operational performance than headline figures distorted by exchange?rate swings.

Conclusion

Novartis AG enters the remainder of 2026 with a portfolio anchored by oncology and cardiovascular blockbusters, supported by a pipeline that could extend growth in key therapeutic areas if upcoming data and regulatory decisions are favorable. The first?quarter 2026 results underscore how established products such as Kisqali, Entresto and Cosentyx are shaping the company’s earnings mix while funding research into new treatments. For US investors following global healthcare names via the NYSE listing, the stock offers exposure to worldwide demand for innovative medicines but also faces familiar sector challenges, including patent expiries, competitive pressures and evolving reimbursement landscapes. How effectively Novartis continues to deliver clinical data, secure approvals and manage pricing will remain central questions for the equity story over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.